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Bp180: Targeting an Autoimmune Antigen 
Bullous pemphigoid (BP) is an autoimmune disorder associated 
with subepidermal blistering and disruption of interactions between 
basal keratinocytes and the cutaneous basement membrane. Sera 
from affected individuals contain antibodies that recognize two dis-
tinct antigenic elements of the hemidesmosome. This membrane-
associated structure has been implicated in the maintenance of der-
mal-epidermal adhesion. BP autoantibodies were used for the initial 
characterization of the target proteins, referred to as BP230 and 
BP180 (or BPAGI and BPAG2, respectively). Affinity-purified 
antibodies from the autoimmune sera revealed that BPAGI and 
BPAG2 are immunologically distinct. More recently, keratinocyte-
derived lambda gtii expression libraries screened with BP autoanti-
bodies yielded cDNA for these proteins. Examination of partial 
coding sequences revealed that the proteins were products of sepa-
rate genes that mapped to different chromosomes. Whereas analysis 
of BP230 coding sequence suggested a membrane-associated cyto-
plasmic protein, the deduced amino acid sequence of a clone for 
BP180 revealed an interesting and unusual configuration. It is a 
transmembrane protein with an unusual orientation: the C-termi-
nus is extracellular (type II orientation). Further, the extracellular 
domain of the protein contained collagen-like regions that might be 
important for cell-matrix interaction. . . 
In this issue, three papers more fully analyze the composItion of 
the BPI80 antigen. All have, as a core, identification of a coding 
sequence for BP180. Each is unique and asks further biochemical 
and biologic questions aimed at determining the structure and the 
functional significance implied by the primary sequence of these 
clones. Hopkinson et al expand the early sequence data to include a 
larger portion of the cytoplasmic domail:. Giudice et ~l present a 
rigorous descnptlOn of the molecular clomng and dISSection of what 
may represent a full-length coding sequence of the human protein. 
Lastly, Li et al find extensive interspecies consetvation of these 
domains in sequences derived from mouse keratinocyte cDNA. The 
discussions revolve around different aspects of computer-generated 
structural modeling as well as implications of clinical findings in 
correlated disorders. 
Hopkinson et al employ BP autoantibodies to isolate human ker-
atinocyte cDNA library sequences. These fragments overlap the 
initially reported clones, but extend toward the N-terminus of the 
protein. A fusion protein was engineered based on these cDNA. 
Antibodies directed against the fusion protein are used in parallel 
studies to show that the reactive N-terminal epitope is located in the 
cytoplasm. Immunofluorescence microscopy, using fusion protein-
directed antiserum, detects the interface between epithelium and 
basement membrane in several tissues that contain bona fide hemi-
desmosome structures and in species as genetically distant as frogs. 
EM analysis of human skin demonstrates that the antibody binds the 
cytoplasmic portion of the hemidesmosome structure. In cultured 
human epidermal cells the staining co-localizes with antibodies to 
BP230, along the substrate attachment plane. Western blot analysis 
of trypsinized epidermal monolayers shows that BP230 is unaf-
fected. By contrast, a large portion of BP180 is extracellular and 
sensitive to digestion. Both the autoimmune and fusion protein-
derived antisera recognize a 55-kDa protected cytoplasmic tryptic 
fragment. 
Giudice et al have subcloned overlapping cDNA providing an 
open reading frame of BP180 that is - 4600 bases long. In addition 
to standard sequence analysis of the clones, PCR evaluation of an 
independently produced keratinocyte cDNA library was used to 
confirm their contiguity. This array of subclones represents a poly-
peptide of 155 kDa, indicating that the 5' -terminus of the BP180 
coding region may not have been identified. Analysis of the struc-
tures predicted by the nucleic sequence produced a model that high-
lights the nature of the C-terminal extracellular domain. This por-
tion of the protein contains a series of 15 collagen domains, ranging 
from 15 to 242 amino acids long. Each domain is characterized by 
proline-rich tandem repeats of the glycine-X-Y tripeptide. Compar-
ison of BP180 sequence with the GenBank nucleic acid database 
showed extensive homology with all reported members of the col-
lagen family and with a chicken corneal collagen, in particular. 
However, there was no significant homology to the nucleotide or 
amino acid sequence ofBP230. Western blot analysis of epidermal 
BPl80 antigen, digested with bacterial collagenase under a variety 
of controlled conditions, confirmed the characterization and locali-
zation of the collagenous ectodomain. It also supports their previous 
studies localizing the BPI80 autoantibody epitope to an extracellu-
lar portion of the major collagen-resistant fragment of the lambda 
gtll clone product. 
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Li et al further analyze BP180 with a study of cDNA clones 
representing 1.8 kb of the homologous mouse gene transcript. The 
significant structural transmembrane and collagenous domains de-
scribed above are identified in mouse BP180 and chicken corneal 
collagen. Between the transmembrane domain and the collagenous 
tail, there is a sequence that is predicted to be highly antigenic. This 
corresponds to the region in which Giudice et al suggest BP autoan-
tibodies and fusion protein-directed antibodies recognize the 
human antigen. An R-G-D (arg-gly-asp) tripeptide is located in one 
of the collagen domains of the mouse sequence. It may be involved 
in integrin-mediated cell attachment, although the homologous 
region of the human sequence is R-G-E (arg-gly-glu). The intracel-
lular domain contains six possible phosphorylation sites as well as a 
recognition site for p34cdc2 kinase, an enzyme involved in the initia-
tion of meiotic and mitotic M phase. It is interesting to hypothesize 
an interaction of the hemidesmosome with cytoskeletal elements 
and that phosphorylation of the BP180 protein triggers an alter-
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ation in the attachment of the cell to the substratum during cell 
division. 
The BP180 protein also serves as at least one of the antigens f~r a 
clinically related subepidermal dermatosis, herpes gestationis. GI~­
dice et al will be reporting further that a target epitope in thiS 
condition is also localized to the short region between the tran.s-
membrane and collagen tail domain. It is fascinating that the data 10 
all three papers indicate that BP180 is a highly conserved trans-
membrane protein of un~sual c.omposition. Furthe:, it serves as ~t 
least one of the target antigens 111 a number of autOImmune condi-
tions. Yet it appears that the autoantibodies from different indivi~u­
als may recognize different epitopes of the polypeptide. Is the Im-
mune response to BP180 polyclonal? Can blister formation ~esulf 
from interaction of the antibody with a cytoplasmic domam ~ 
BP180? What is the interrelationship between BP180, the heml -
desmosome, and dermal-epidermal attachment? 
Epidermal IgG Deposits and the Diagnosis of SCLE 
Also in this issue, autoimmune antibodies are shown to playa signifi-
cant role in confirmation of the clinical diagnosis of subacute cutane-
ous lupus erythematosus (SCLE) as a distinct subset of LE patients. 
David-Bajar et al have systematically reviewed the clinical, histo-
logic, and serologic criteria used to distinguish SCLE from discoid 
(DLE) and systemic (SLE) lupus. 
The description .ofSCLE by Sontheimer, Thomas, and Gilliam in 
1979 drew renewed attention to the role of autoantibodies in lupus. 
SCLE was differentiated from DLE in patients with discoid lesions 
where there was photosensitivity and photo distribution of lesions, 
but no scarring. These individuals showed only a mild systemic 
disease without renal or central nervous system involvement. Most 
had anti-Ro/SSA antibodies and HLA-DR3 tissue type. Anti-Rol 
SSA antibodies show particulate epidermal localization in various 
experimental models including UV-irradiated suction blisters and 
cultured keratinocytes. This pattern is also seen when human skin 
grafts onto immunosuppressed mice are injected with anti-Ro/SSA 
antibodies. Although anti-Ro/SSA antibodies target a 60-kDa RNA 
binding protein, anti-Ro binding occurred on the cell surface as well 
as in the nucleus and cyt.oplasm of keratinocytes and was dependent 
on protein synthesis and microfilament production, but not on cell-
cycle phase. In neonatal lupus erythematosus, SCLE lesions are ex-
pressed transiently in offspring of women with anti-Ro/SSA anti-
bodies, implying that placental transmission of the antibody induces 
the disorder. 
In this study, the authors reaffirm SCLE as a distinct subset of 
lupus and define the clinical and histologic findings that are most 
helpful in distinguishing SCLE from DLE. Twenty-seven patients 
were classified on the basis of cutaneous examination to fall into one 
of three groups: 1) DLE (with or without SLE), 2) SCLE (with or 
without SLE) , or 3) SLE patients without D LE or SCLE lesions. ~he 
clinical finding most important for diagnosis of D LE was induratiOn 
of the lesions; localization to the face or scalp and scarring were also 
useful criteria. Superficial inflammation, photosensitivity, and sym-
metric photodistribution of lesions were principal determinants for 
SCLE. Histologic evaluation of 13 features confirmed that the de-
gree of hyperkeratosis and the depth and intensity of dermal inflam-
mation were the most useful diagnostic discriminators. The II1:0st 
striking difference between DLE and SCLE was in the distribution 
ofIgG staining. DLE lesions had particulate staining of the dermali 
epidermal junction (DE]), whereas SCLE lesions had epidern:a 
staining. Both DLE and SCLE lesions showed IgM associated With 
the DE]. In non-lesional regions, all SCLE patients demonstrated 
both IgG and IgM, whereas DLE patients only showed immuno-
reactants if the systemic condition was present. Although thes~ 
direct immunofluorescence measurements may be the most usefu 
test for diagnosis of SCLE, it is not clear whether the stainin~ ~ 
more directly correlated with anti-Ro/SSA antibodies or Wit 
SCLE. 
Taken together these four studies present intriguing steps toward 
the elucidation of which came first, the antibody or the lesion. Th.ey 
also bring forward further questions as to the nature of antibodies 
that recognize nuclear or cytoplasmic rather than extracellul~r dr 
mains of target proteins. How do these epitopes stimulate antlbo l 
production? What is the mechanism of their interactions? H?W ~ 
they influence the normal cellular processes to effect a disease. 
Autoantibodies, whether cause or effect ofBP and SCLE, will serve 
as useful tools for the dissection of these disorders. 
